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TREATMENT WITH CHONDROITIN SULFATE REDUCES CARTILAGE
VOLUME LOSS IN KNEE OA PATIENTS ASSESSED BY MRI: A RANDOMIZED,
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Purpose: Disease modifying osteoarthritis drug (DMOAD) development re-
mains a challenge. The DMOAD effect of chondroitin sulfate (CS), shown by
a reduction in joint space narrowing (X-ray) in knee OA [1–3], needs to be
further objectiﬁed by quantitative cartilage imaging. The aim of this study
was to determine the effect of CS treatment on the extent of cartilage loss,
subchondral bone marrow lesion (BML) size, and severity of synovitis in pa-
tients with symptomatic knee OA using magnetic resonance imaging (MRI).
Methods: This pilot study was a multicentre, randomized, double-blind,
controlled trial of CS (Condrosan®, Bioiberica, Barcelona, Spain) 800 mg
once daily vs. placebo for 6 months followed by an open label period of 6
months in which patients from both groups received CS 800 mg once daily.
Patients with primary knee OA and clinical signs of synovitis (joint swelling
and/or effusion) were included. MRI was performed at baseline, 6, and 12
months. The cartilage volume was quantiﬁed using 3D reconstruction of
the MR images. The BML size, severity of synovitis, and meniscal extrusion
were assessed on a semi-quantitative scoring system.
Results: 70 patients were enrolled and 62 (88.6%) completed the study.
Baseline characteristics were similar between the two treatment groups
with the exception of age (59.7±9.4, 64.6±9.6 years old [mean±SD],
respectively; p=0.03). Patients receiving CS treatment for 12 months com-
pared to the patients receiving placebo (6 months placebo followed by
6 months CS) experienced a signiﬁcant reduction in cartilage volume
loss in the lateral compartment at 6 (-1.1±3.3%, -3.0±4.5%; p=0.05) and
12 months (-1.0±3.8%, -3.9±4.5%; p=0.013). These differences were even
more pronounced in OA patients without medial meniscal extrusion (6
months, -1.1±3.4%, -3.6±4.3%; p=0.02; 12 months, -1.1±3.8%, -4.3±4.3%;
p=0.008). Patients on CS treatment also presented reduction in BML score
at 6 months and a marked reduction at 12 months (global knee, -0.7±2.6,
0.6±2.1; p=0.06; lateral compartment, -0.4±1.1, 0.7±1.4; p=0.002). No
difference was found in synovitis severity between the 2 treatment groups
at 6 months. Interestingly, the patients in the CS treatment group, who
were receiving concomitant non-steroidal anti-inﬂammatory drug (NSAID)
treatment, demonstrated a statistically signiﬁcant reduction in synovial
membrane thickness compared to the placebo group (1.3±0.3 mm, 1.6±0.3
mm; p=0.03), and a reduction in synovitis score (3.0±1.9, 4.5±1.6; p=0.09),
as well as lower incidence of joint swelling (p=0.09).
Conclusions: CS treatment was found to signiﬁcantly reduce the cartilage
volume loss in knee OA starting as early as 6 months into treatment.
This was associated with a concomitant reduction in BML size supporting
the hypothesis of their role in cartilage volume loss. CS treatment in
combination with NSAIDs also reduced severity of synovitis. These ﬁndings
further support the DMOAD effect of CS and provide new information on
its mode of action on the OA process.
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Purpose: To assess the effect of viscosupplementation with hylan G-F 20
on the progression of cartilage loss over two years in patients with knee
osteoarthritis (OA).
Methods: A single-blind, parallel control group pilot clinical trial was
performed in 78 eligible patients with symptomatic knee OA (Kellgren
Lawrence grade II and III). Patients were assigned to either an intervention
group (n=39, receiving four courses (3×2.0cc) of intra-articular HYLAN-G-F
20 injections at six months intervals or a control group (n=39, without
injections but receiving usual care for OA). Magnetic resonance imaging
the target knee was performed at baseline, 6, 12, and 24 months and
images were analysed blinded both to patient group and sequence Tibial
cartilage volume, tibiofemoral cartilage defects and bone marrow lesions
were assessed at baseline and follow up
Results: 55 subjects (71%) completed 2-year follow up. There was no
signiﬁcant difference in age, gender, BMI, baseline cartilage volume, bone
marrow lesions and bone area in those who completed and those who did
not (all P>0.13). Analysis of completers demonstrated a signiﬁcantly re-
duced annual percentage rate of medial, lateral and total tibial cartilage loss
in the intervention group (mean±SD, -0.3±2.7%, -1.4±4.3% and -0.5±2.3%)
compared with the control group (2.3±2.6%, 1.4±2.6%, 1.6±1.8%, P=0.001,
0.005 and 0.001 for difference, respectively). The intervention group also
showed a signiﬁcant reduction in the increase of cartilage defect score
in the medial and total tibiofemoral compartments (0.1±1.3 and 0.5±2.0)
compared with the control group (0.8±1.5 and 1.6±2.0, all P=0.05). There
was no signiﬁcant difference of change in bone marrow lesions between
the intervention and control groups.
Conclusions: 6 monthly intra-articular injections of HYLAN-G-F 20 ad-
ministered without regard to symptoms have a beneﬁcial effect on knee
cartilage preservation as measured by both cartilage volume and cartilage
defect score. Over two years, the control group continues to lose cartilage
while there is no signiﬁcant loss of cartilage in the HYLAN G-F treated
group. HYLAN G-F 20 could be further evaluated in larger trials as a possible
disease-modifying agent in patients with knee OA.
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EFFICACY OF DIETING OR EXERCISE VS. CONTROL IN OBESE KNEE
OSTEOARTHRITIS PATIENTS AFTER A CLINICALLY SIGNIFICANTWEIGHT
LOSS: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL
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Purpose: Patients with knee osteoarthritis, who are overweight, should be
encouraged to lose weight and maintain their weight at a lower level; basic
therapy includes reduction in weight in the obese and exercises to keep in
shape.
Our objective was to compare the symptomatic eﬃcacy of 1-year dieting
or exercise vs. control in obese patients after a clinically signiﬁcant weight
loss. We hypothesised that a continued dietary program rather than an
exercise regimen with the same amount of attention should maintain a
clinically signiﬁcant weight loss in obese patients with knee OA.
Methods: Obese individuals (>50 years) having knee OA (ACR criteria), and
motivated for weight loss, were enrolled in a 16-week course, provided a
very-low energy formula diet for 8-weeks and 8 weeks on normal hypo-
energetic foods. They were then randomised to either 1-year maintenance
program with [D] continuous dietary consultations, or [E] exercise pro-
grams lead by a physiotherapist, or [C] a control group receiving no support
from the project team for 1 year. The amount of attention was exactly
the same in D and E, preventing performance and detection bias. The pri-
mary endpoint was the number of patients fulﬁlling the OMERACT-OARSI
response criteria. The statistical analyses were based on a non-responder
intention-to-treat population (baseline observation carried forward); i.e. all
patients enrolled in the ﬁrst 16-weeks. Analyses were based on 1-factor
ANCOVA adjusting for baseline and absolute risk differences following 2×2
(chi-square) contingency tables.
Results: 192 participants, mean age 63 years (SD 6), mean weight 103.2 kg
(15.0), and BMI of 37.3 (4.8) were randomized (1:1:1; 64 patients in each
group). As illustrated in the ﬁgure, mean weight losses following 16-weeks
initiating weight loss and 1 year on either D, E, and C were 10.9, 6.3, and 8.2
kg, respectively (ANCOVA: P=0.003) at week 68; D lost signiﬁcantly more
weight than did E: 4.6 (95%CI 2.0, 7.3; P<0.001). The primary outcome
- the number of patients having an OMERACT-OARSI response at week
68 in the D, E, and C groups were 30 (47%), 24 (38%), and 30 (47%),
respectively (P=0.47); apparently with no signiﬁcant difference between
D and E, with an absolute difference of 8.7% (-7.7, 26.4%; P=0.77). There
